Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
Bioact Mater ; 31: 463-474, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37701451

ABSTRACT

Human induced pluripotent stem cell derived cardiac fibroblasts (hiPSC-CFs) play a critical role in modeling human cardiovascular diseases in vitro. However, current culture substrates used for hiPSC-CF differentiation and expansion, such as Matrigel and tissue culture plastic (TCPs), are tissue mismatched and may provide pathogenic cues. Here, we report that hiPSC-CFs differentiated on Matrigel and expanded on tissue culture plastic (M-TCP-iCFs) exhibit transcriptomic hallmarks of activated fibroblasts limiting their translational potential. To alleviate pathogenic activation of hiPSC-CFs, we utilized decellularized extracellular matrix derived from porcine heart extracellular matrix (HEM) to provide a biomimetic substrate for improving hiPSC-CF phenotypes. We show that hiPSC-CFs differentiated and expanded on HEM (HEM-iCFs) exhibited reduced expression of hallmark activated fibroblast markers versus M-TCP-iCFs while retaining their cardiac fibroblast phenotype. HEM-iCFs also maintained a reduction in expression of hallmark genes associated with pathogenic fibroblasts when seeded onto TCPs. Further, HEM-iCFs more homogenously integrated into an hiPSC-derived cardiac organoid model, resulting in improved cardiomyocyte sarcomere development. In conclusion, HEM provides an improved substrate for the differentiation and propagation of hiPSC-CFs for disease modeling.

2.
J Tissue Eng Regen Med ; 16(9): 799-811, 2022 09.
Article in English | MEDLINE | ID: mdl-35689600

ABSTRACT

Acute cardiac injuries occur in 20%-25% of hospitalized COVID-19 patients. Herein, we demonstrate that human cardiac organoids (hCOs) are a viable platform to model the cardiac injuries caused by COVID-19 hyperinflammation. As IL-1ß is an upstream cytokine and a core COVID-19 signature cytokine, it was used to stimulate hCOs to induce the release of a milieu of proinflammatory cytokines that mirror the profile of COVID-19 cytokine storm. The IL-1ß treated hCOs recapitulated transcriptomic, structural, and functional signatures of COVID-19 hearts. The comparison of IL-1ß treated hCOs with cardiac tissue from COVID-19 autopsies illustrated the critical roles of hyper-inflammation in COVID-19 cardiac insults and indicated the cardioprotective effects of endothelium. The IL-1ß treated hCOs thus provide a defined and robust model to assess the efficacy and potential side effects of immunomodulatory drugs, as well as the reversibility of COVID-19 cardiac injuries at baseline and simulated exercise conditions.


Subject(s)
COVID-19 , Cytokine Release Syndrome , Heart Diseases , COVID-19/complications , Cytokine Release Syndrome/virology , Cytokines/metabolism , Heart Diseases/virology , Humans , Models, Biological , Organoids
3.
J Bioeth Inq ; 19(1): 21-24, 2022 03.
Article in English | MEDLINE | ID: mdl-35362927

ABSTRACT

Despite optimistic reports about the results of amputation for advanced vascular disease, the patient's assessment of advantages and disadvantages is seldom acknowledged. A detailed social study of 67 amputees has revealed considerable disparity between the patient's views and those of the medical staff. About a third of the patients are forced to retire from active work by the amputation; about three-quarters report a serious decline in their social activities; only about half are really independent with prostheses in the long term; a quarter report severe and intractable symptoms related to their amputation stumps; only about a quarter feel that the amputation was definitely beneficial; and only about one in five feel that the medical staff have provided adequate support during their hospital stay. Amputees face physical and financial disability, isolation, and discomfort. Every effort must be made to explain the implications of amputation honestly and realistically and to ensure continuing patient assessment and support.


Subject(s)
Amputees , Artificial Limbs , Amputation, Surgical , Amputation Stumps , Emotions , Humans
4.
bioRxiv ; 2022 Feb 01.
Article in English | MEDLINE | ID: mdl-35132419

ABSTRACT

Acute cardiac injuries occur in 20-25% of hospitalized COVID-19 patients. Despite urgent needs, there is a lack of 3D organotypic models of COVID-19 hearts for mechanistic studies and drug testing. Herein, we demonstrate that human cardiac organoids (hCOs) are a viable platform to model the cardiac injuries caused by COVID-19 hyperinflammation. As IL-1ßis an upstream cytokine and a core COVID-19 signature cytokine, it was used to stimulate hCOs to induce the release of a milieu of proinflammatory cytokines that mirror the profile of COVID-19 cytokine storm. The IL-1 ß treated hCOs recapitulated transcriptomic, structural, and functional signatures of COVID-19 hearts. The comparison of IL-1ß treated hCOs with cardiac tissue from COVID-19 autopsies illustrated the critical roles of hyper-inflammation in COVID-19 cardiac insults and indicated the cardioprotective effects of endothelium. The IL-1ß treated hCOs also provide a viable model to assess the efficacy and potential side effects of immunomodulatory drugs, as well as the reversibility of COVID-19 cardiac injuries at baseline and simulated exercise conditions.

5.
FASEB J ; 35(9): e21799, 2021 09.
Article in English | MEDLINE | ID: mdl-34339055

ABSTRACT

Cardiac fibroblasts (CFBs) support heart function by secreting extracellular matrix (ECM) and paracrine factors, respond to stress associated with injury and disease, and therefore are an increasingly important therapeutic target. We describe how developmental lineage of human pluripotent stem cell-derived CFBs, epicardial (EpiC-FB), and second heart field (SHF-FB) impacts transcriptional and functional properties. Both EpiC-FBs and SHF-FBs exhibited CFB transcriptional programs and improved calcium handling in human pluripotent stem cell-derived cardiac tissues. We identified differences including in composition of ECM synthesized, secretion of growth and differentiation factors, and myofibroblast activation potential, with EpiC-FBs exhibiting higher stress-induced activation potential akin to myofibroblasts and SHF-FBs demonstrating higher calcification and mineralization potential. These phenotypic differences suggest that EpiC-FBs have utility in modeling fibrotic diseases while SHF-FBs are a promising source of cells for regenerative therapies. This work directly contrasts regional and developmental specificity of CFBs and informs CFB in vitro model selection.


Subject(s)
Cell Lineage/physiology , Myofibroblasts/physiology , Pluripotent Stem Cells/physiology , Cell Differentiation/physiology , Cells, Cultured , Extracellular Matrix/physiology , Humans , Myocardium/pathology , Myocytes, Cardiac/physiology , Phenotype , Transcription, Genetic/physiology
6.
Int J Mol Sci ; 22(16)2021 Aug 06.
Article in English | MEDLINE | ID: mdl-34445185

ABSTRACT

Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been widely used for disease modeling and drug cardiotoxicity screening. To this end, we recently developed human cardiac organoids (hCOs) for modeling human myocardium. Here, we perform a transcriptomic analysis of various in vitro hiPSC-CM platforms (2D iPSC-CM, 3D iPSC-CM and hCOs) to deduce the strengths and limitations of these in vitro models. We further compared iPSC-CM models to human myocardium samples. Our data show that the 3D in vitro environment of 3D hiPSC-CMs and hCOs stimulates the expression of genes associated with tissue formation. The hCOs demonstrated diverse physiologically relevant cellular functions compared to the hiPSC-CM only models. Including other cardiac cell types within hCOs led to more transcriptomic similarities to adult myocardium. hCOs lack matured cardiomyocytes and immune cells, which limits a complete replication of human adult myocardium. In conclusion, 3D hCOs are transcriptomically similar to myocardium, and future developments of engineered 3D cardiac models would benefit from diversifying cell populations, especially immune cells.


Subject(s)
Myocardium/metabolism , Myocytes, Cardiac/metabolism , Organoids/metabolism , Transcriptome , Adult , Cells, Cultured , Humans , Induced Pluripotent Stem Cells/cytology , Induced Pluripotent Stem Cells/metabolism , Myocardium/cytology , Myocytes, Cardiac/cytology , Organoids/cytology
7.
Nat Biomed Eng ; 4(4): 446-462, 2020 04.
Article in English | MEDLINE | ID: mdl-32284552

ABSTRACT

Environmental factors are the largest contributors to cardiovascular disease. Here we show that cardiac organoids that incorporate an oxygen-diffusion gradient and that are stimulated with the neurotransmitter noradrenaline model the structure of the human heart after myocardial infarction (by mimicking the infarcted, border and remote zones), and recapitulate hallmarks of myocardial infarction (in particular, pathological metabolic shifts, fibrosis and calcium handling) at the transcriptomic, structural and functional levels. We also show that the organoids can model hypoxia-enhanced doxorubicin cardiotoxicity. Human organoids that model diseases with non-genetic pathological factors could help with drug screening and development.


Subject(s)
Drug Evaluation, Preclinical/methods , Heart/drug effects , Models, Cardiovascular , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Organoids/drug effects , Cardiotoxicity/metabolism , Cardiotoxicity/pathology , Drug Development , Humans , Myocardial Infarction/chemically induced , Myocardial Infarction/genetics , Organoids/metabolism , Organoids/pathology , Oxygen/metabolism
8.
Can J Cardiol ; 35(2): 160-168, 2019 02.
Article in English | MEDLINE | ID: mdl-30760422

ABSTRACT

BACKGROUND: Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain. METHODS: We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male). RESULTS: Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians. CONCLUSIONS: Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation.


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Hemorrhage/etiology , Risk Assessment/methods , Stroke/etiology , Aged , Atrial Fibrillation/drug therapy , Canada/epidemiology , Female , Hemorrhage/epidemiology , Humans , Incidence , Male , Risk Factors , Sex Factors , Stroke/epidemiology , Stroke/prevention & control
9.
J Vis Exp ; (125)2017 07 10.
Article in English | MEDLINE | ID: mdl-28715381

ABSTRACT

There are several different techniques for measuring telomere length, each with their own advantages and disadvantages. The traditional approach, Telomere Restriction Fragment (TRF) analysis, utilizes a DNA hybridization technique whereby genomic DNA samples are digested with restriction enzymes, leaving behind telomere DNA repeats and some sub-telomeric DNA. These are separated by agarose gel electrophoresis, transferred to a filter membrane and hybridized to oligonucleotide probes tagged with either chemiluminescence or radioactivity to visualize telomere restriction fragments. This approach, while requiring a larger quantity of DNA than other techniques such as PCR, can measure the telomere length distribution of a population of cells and allows measurement expressed in absolute kilobases. This manuscript demonstrates a modified DNA hybridization procedure for determining telomere length. Genomic DNA is first digested with restriction enzymes (that do not cut telomeres) and separated by agarose gel electrophoresis. The gel is then dried and the DNA is denatured and hybridized in situ to a radiolabeled oligonucleotide probe. This in situ hybridization avoids loss of telomere DNA and improves signal intensity. Following hybridization, the gels are imaged utilizing phosphor screens and the telomere length is quantified using a graphing program. This procedure was developed by the laboratories of Drs. Woodring Wright and Jerry Shay at the University of Texas Southwestern1,2. Here, we present a detailed description of this procedure, with some modifications.


Subject(s)
DNA Restriction Enzymes/genetics , DNA/genetics , In Situ Hybridization/methods , Telomere/metabolism , Humans
10.
Am J Cardiol ; 120(4): 582-587, 2017 Aug 15.
Article in English | MEDLINE | ID: mdl-28666577

ABSTRACT

Using data collected from 2 national atrial fibrillation (AF) primary care physician chart audits (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation [FREEDOM AF] and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation [CONNECT AF]), we evaluated the frequency of, and factors associated with, the use of cardiovascular (CV) evidence-based therapies in Canadian AF outpatients with at least 1 CV risk factor or co-morbidity. Of the 11,264 patients enrolled, 9,495 (84.3%) were eligible for one or more CV evidence-based therapies. The proportions of patients with AF receiving all eligible guideline-recommended therapies were 40.8% of patients with coronary artery disease, 48.9% of patients with diabetes mellitus, 40.2% of patients with heart failure, 96.7% of patients with hypertension, and 55.1% of patients with peripheral arterial disease. Factors that were independently associated with nonreceipt of all indicated evidence-based therapies included sinus rhythm rather than AF at baseline and liver disease. In conclusion, although most Canadian outpatients with AF have CV risk factors or co-morbidities, a substantial portion of these patients did not receive all guideline-recommended therapies. These findings suggest that there is an opportunity to improve the quality of care for patients with AF in Canada.


Subject(s)
Atrial Fibrillation/therapy , Evidence-Based Medicine/standards , Outpatients , Physicians, Primary Care/education , Practice Guidelines as Topic , Risk Assessment , Stroke/prevention & control , Aged , Atrial Fibrillation/complications , Canada/epidemiology , Clinical Competence , Female , Humans , Incidence , Male , Physicians, Primary Care/standards , Program Evaluation , Registries , Risk Factors , Stroke/epidemiology , Stroke/etiology
11.
Worldviews Evid Based Nurs ; 14(4): 265-273, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28432853

ABSTRACT

BACKGROUND: It is estimated that between 80% and 99% of alarms in the clinical areas are in actionable alarms (Gross, Dahl, & Nielson). Alarm management is one of the Joint Commission's National Patient Safety Goals (2014) because sentinel events have directly been linked to the devices generating these alarms. PURPOSE: At an acute care facility in Boston, a multidisciplinary team consisting of Nursing, Biomedical Engineers, Patient Safety and Providers was formed to conduct a pilot study on the state of telemetry alarms on a surgical floor. METHODS: An evidence-based approach was taken utilizing Philips Real-time data exporter alarms tracking software to capture all telemetry alarms during a 43-day time span. Likewise, noise meters were placed near telemetry alarm speakers to track decibel levels within the aforementioned timeframe for 21 days. Analysis of the data showed that clinically insignificant Premature Ventricular Contractions (PVC) alarms accounted for more than 40% of all alarms in the unit within the time span, while also contributing to an average noise level of 58.49 dB. In response to the data, the interdisciplinary team approved to permanently default the settings for PAIR PVC, MULTIFORM PVC, and RUN PVC alarms to off. RESULTS: The results showed a 54% decrease in the rate of alarms per bed per day, and an average noise reduction of 2.3 dB between the two selected noise measurement areas. LINKING EVIDENCE TO ACTION: Organizing a multidisciplinary team provides an effective framework toward analyzing and addressing cardiac telemetry alarm fatigue. Looking at quantitative datasets for clinical care areas through various lenses helps identify opportunities for improvement in regards to highlighting alarms that are not actionable. Pilot changes to alarm parameters can be tested for their environmental impact in the care area.


Subject(s)
Clinical Alarms/adverse effects , Evidence-Based Practice/methods , Fatigue/etiology , Monitoring, Physiologic/psychology , Noise/adverse effects , Boston , Burnout, Professional/prevention & control , Burnout, Professional/psychology , Clinical Alarms/standards , Critical Care Nursing , Fatigue/complications , Humans , Monitoring, Physiologic/adverse effects , Monitoring, Physiologic/methods , Nurses/psychology , Pilot Projects , Quality Improvement , Telemetry/adverse effects , Telemetry/instrumentation , Telemetry/methods , Ventricular Premature Complexes/complications , Ventricular Premature Complexes/psychology , Workforce
12.
J Med Genet ; 54(6): 390-398, 2017 06.
Article in English | MEDLINE | ID: mdl-28264985

ABSTRACT

BACKGROUND: Variable expressivity and incomplete penetrance between individuals with identical long QT syndrome (LQTS) causative mutations largely remain unexplained. Founder populations provide a unique opportunity to explore modifying genetic effects. We examined the role of a novel synonymous KCNQ1 p.L353L variant on the splicing of exon 8 and on heart rate corrected QT interval (QTc) in a population known to have a pathogenic LQTS type 1 (LQTS1) causative mutation, p.V205M, in KCNQ1-encoded Kv7.1. METHODS: 419 adults were genotyped for p.V205M, p.L353L and a previously described QTc modifier (KCNH2-p.K897T). Adjusted linear regression determined the effect of each variant on QTc, alone and in combination. In addition, peripheral blood RNA was extracted from three controls and three p.L353L-positive individuals. The mutant transcript levels were assessed via qPCR and normalised to overall KCNQ1 transcript levels to assess the effect on splicing. RESULTS: For women and men, respectively, p.L353L alone conferred a 10.0 (p=0.064) ms and 14.0 (p=0.014) ms increase in QTc and in men only a significant interaction effect in combination with the p.V205M (34.6 ms, p=0.003) resulting in a QTc of ∼500 ms. The mechanism of p.L353L's effect was attributed to approximately threefold increase in exon 8 exclusion resulting in ∼25% mutant transcripts of the total KCNQ1 transcript levels. CONCLUSIONS: Our results provide the first evidence that synonymous variants outside the canonical splice sites in KCNQ1 can alter splicing and clinically impact phenotype. Through this mechanism, we identified that p.L353L can precipitate QT prolongation by itself and produce a clinically relevant interactive effect in conjunction with other LQTS variants.


Subject(s)
KCNQ1 Potassium Channel/genetics , RNA Splicing/genetics , Romano-Ward Syndrome/genetics , Arrhythmias, Cardiac/genetics , Exons/genetics , Female , Genotype , Humans , Male , Mutation/genetics , Phenotype
13.
Can J Cardiol ; 33(6): 814-821, 2017 06.
Article in English | MEDLINE | ID: mdl-28347582

ABSTRACT

BACKGROUND: Inherited heart rhythm disorders (IHRDs) are complex and uncommon arrhythmogenic conditions that can lead to sudden unexpected death in seemingly healthy individuals. Multidisciplinary programs can assist in the diagnostic testing of potentially affected individuals and their family members. METHODS: Patients evaluated in a specialized adult and pediatric IHRD clinic between April 2013 and February 2015 were characterized. The total costs per evaluation and diagnosis were calculated. Patients were divided according to referral indication (primary referral or family member). RESULTS: A total of 618 patients were evaluated (age 36 ± 21 years; 52% male), of which 274 (44%) were primary referrals and 344 (56%) were family members referred for cascade screening. Overall, 47% had at least 1 follow-up visit. Patients had a median of 3 tests; primary referrals required more tests (4 vs 2; P < 0.01). The median cost per patient was $1340 CAD. Evaluation of the primary referrals was costlier than family members ($3096 vs $983; P < 0.01). A definite or probable diagnosis was determined in 464 patients (77%), with no difference according to patient type (P = 0.18). The total cost per diagnosis was $4021 in primary referrals compared with $1277 in family members (P < 0.01). CONCLUSIONS: Clinical evaluation of patients with suspected IHRD results in a high diagnostic yield and costs aligned with other complex disorders involving multidisciplinary clinics. Evaluation costs are expectedly higher in primary referrals compared with targeted family screening.


Subject(s)
Arrhythmias, Cardiac/diagnosis , Health Care Costs , Referral and Consultation/economics , Adult , Arrhythmias, Cardiac/congenital , Arrhythmias, Cardiac/economics , British Columbia , Costs and Cost Analysis , Female , Follow-Up Studies , Humans , Male , Retrospective Studies
14.
Heart Rhythm ; 14(6): 801-807, 2017 06.
Article in English | MEDLINE | ID: mdl-28232263

ABSTRACT

BACKGROUND: Progression from paroxysmal to persistent atrial fibrillation (AF) has important clinical implications and is relevant to the management of patients with AF. OBJECTIVE: The purpose of this study was to define the long-term rate of progression from paroxysmal to persistent AF and the relevant clinical variables. METHODS: The Canadian Registry of Atrial Fibrillation enrolled patients after a first electrocardiographic diagnosis of paroxysmal AF. Associations between baseline characteristics and clinical outcomes were evaluated using a multivariable Cox proportional hazard model and a competing risk model accounting for death as a competing risk, where appropriate. RESULTS: We enrolled 755 patients (61.7% men) aged between 14 and 91 years (mean age 61.2 ± 14.2 years). The median follow-up was 6.35 years (interquartile range 2.93-10.04 years), with a rate of progression to persistent AF at 1, 5, and 10 years was 8.6%, 24.3%, and 36.3%, respectively. All-cause mortality was 30.3% at 10 years. Factors associated with AF progression were increasing age (hazard ratio [HR] 1.40; 95% confidence interval [CI] 1.23-1.60, for each 10-year increment), mitral regurgitation (HR 1.87; 95% CI 1.28-2.73), left atrial dilatation (HR 3.01; 95% CI 2.03-4.47), aortic stenosis (HR 2.40; 95% CI 1.05-5.48), and left ventricular hypertrophy (HR .47; 95% CI 1.04-2.08). Factors associated with a lower rate of progression were a faster heart rate during AF (HR 0.94; 95% CI 0.92-0.96 per 5-beat/min increment) and angina (HR 0.54; 95% CI 0.38-0.77). After accounting for death as a competing risk, left ventricular hypertrophy and aortic stenosis were no longer significant. CONCLUSION: Within 10 years of presenting with paroxysmal AF, >50% of patients will progress to persistent AF or be dead. Increasing age, mitral regurgitation, aortic stenosis, left ventricular hypertrophy, and left atrial dilatation were associated with progression to persistent AF.


Subject(s)
Atrial Fibrillation/diagnosis , Electrocardiography/methods , Forecasting , Registries , Risk Assessment/methods , Tachycardia, Paroxysmal/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Atrial Fibrillation/epidemiology , Atrial Fibrillation/physiopathology , Canada/epidemiology , Cause of Death/trends , Disease Progression , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Survival Rate/trends , Tachycardia, Paroxysmal/epidemiology , Tachycardia, Paroxysmal/physiopathology , Young Adult
15.
Circ Cardiovasc Genet ; 10(1)2017 Jan.
Article in English | MEDLINE | ID: mdl-28196901

ABSTRACT

BACKGROUND: Long QT syndrome confers susceptibility to ventricular arrhythmia, predisposing to syncope, seizures, and sudden death. While rare globally, long QT syndrome is ≈15× more common in First Nations of Northern British Columbia largely because of a known mutation in KCNQ1. However, 2 large multigenerational families were affected, but negative for the known mutation. METHODS AND RESULTS: Long QT syndrome panel testing was carried out in the index case of each family, and clinical information was collected. Cascade genotyping was performed. Biochemical and myocyte-based assays were performed to evaluate the identified gene variant for loss-of-function activity. Index cases in these 2 families harbored a novel ANK2 c.1937C>T variant (p.S646F). An additional 16 carriers were identified, including 2 with structural heart disease: one with cardiomyopathy resulting in sudden death and the other with congenital heart disease. For all carriers of this variant, the average QTc was 475 ms (±40). Although ankyrin-B p.S646F is appropriately folded and expressed in bacteria, the mutant polypeptide displays reduced expression in cultured H9c2 cells and aberrant localization in primary cardiomyocytes. Furthermore, myocytes expressing ankyrin-B p.S646F lack normal membrane targeting of the ankyrin-binding partner, the Na/Ca exchanger. Thus, ankyrin-B p.S646F is a loss-of-function variant. CONCLUSIONS: We identify the first disease-causing ANK2 variant localized to the membrane-binding domain resulting in reduced ankyrin-B expression and abnormal localization. Further study is warranted on the potential association of this variant with structural heart disease given the role of ANK2 in targeting and stabilization of key structural and signaling molecules in cardiac cells.


Subject(s)
Ankyrins/genetics , Arrhythmias, Cardiac/genetics , Genetic Variation , Indians, North American/genetics , Long QT Syndrome/genetics , Adolescent , Adult , Aged , Animals , Ankyrins/chemistry , Ankyrins/metabolism , Arrhythmias, Cardiac/diagnosis , Arrhythmias, Cardiac/ethnology , Arrhythmias, Cardiac/metabolism , British Columbia/epidemiology , Cell Line , Child , Child, Preschool , Electrocardiography , Female , Genetic Predisposition to Disease , Humans , Long QT Syndrome/diagnosis , Long QT Syndrome/ethnology , Long QT Syndrome/metabolism , Male , Mice, Knockout , Middle Aged , Myocytes, Cardiac/metabolism , Phenotype , Protein Binding , Protein Interaction Domains and Motifs , Protein Stability , Rats , Sodium-Calcium Exchanger/metabolism , Structure-Activity Relationship , Transfection
16.
J Interv Card Electrophysiol ; 47(2): 163-170, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27394160

ABSTRACT

BACKGROUND: The protective effect of beta-blockers in patients with inherited Long-QT syndrome is well established. Recent reports have suggested that beta-blockers are not equally effective in Long-QT (LQT). Bisoprolol is an attractive candidate for use in LQT because of its cardioselective properties and favorable side-effect profile. METHODS: We performed a retrospective cohort study of 114 consecutive patients with gene-positive Long-QT syndrome type 1 (LQT1) or Long-QT syndrome type 2 (LQT2) treated with bisoprolol, nadolol or atenolol with a total of 580 person-years of follow-up. Electrocardiogram (ECG) parameters and cardiac events during follow-up were compared. In addition, exercise treadmill testing was performed in bisoprolol-treated patients. RESULTS: Fifty-nine patients were treated with bisoprolol, 39 with atenolol and 16 with nadolol. Overall, 59 % were females and 62 % had LQT1. Baseline heart rate and corrected QT (QTc) interval were similar between the groups. QTc shortening was observed in individuals on bisoprolol (ΔQTc -5 ± 31 ms; p = 0.049) and nadolol (ΔQTc -13 ± 16 ms; p = 0.02) but not on atenolol (ΔQTc +9 ± 24 ms; p = 0.16). Median follow-up was similar for bisoprolol and nadolol (3 years), but longer for atenolol (6 years; p = 0.03); one cardiac event occurred in the bisoprolol group (1.7 %) and two events occurred in the atenolol group (5.1 %; p = 0.45), whereas none occurred in nadolol-treated patients. Beta-blocker efficacy was not affected by the underlying genotype. The antiadrenergic effect of bisoprolol correlated with the reduction of peak heart rates at exercise testing. CONCLUSIONS: Bisoprolol treatment results in QTc shortening in gene-positive LQT1 and LQT2 patients and is well tolerated during long-term administration. The equivalence of bisoprolol for protection from ventricular arrhythmia in LQT patients compared to established beta-blockers remains unknown. Further large-scale studies are required.


Subject(s)
Bisoprolol/administration & dosage , Electrocardiography/drug effects , Long QT Syndrome/drug therapy , Romano-Ward Syndrome/diagnosis , Romano-Ward Syndrome/drug therapy , Adrenergic beta-1 Receptor Antagonists , Adult , Canada , Cardiotonic Agents/administration & dosage , Cohort Studies , Female , Heart Rate/drug effects , Humans , Long QT Syndrome/diagnosis , Male , Retrospective Studies , Treatment Outcome
17.
Can J Cardiol ; 32(3): 336-43, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26476851

ABSTRACT

BACKGROUND: Canadian atrial fibrillation (AF) guidelines recommend that all AF patients be risk stratified with respect to stroke and bleeding, and that most should receive antithrombotic therapy. METHODS: As part of the Canadian Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) chart audit, data were collected on 4670 patients ≥ 18 years old without significant valvular heart disease from the primary care practices of 474 physicians (February to September, 2011). RESULTS: Physicians did not provide an estimate of stroke and bleeding risk in 15% and 25% of patients, respectively. When risks were provided, they were on the basis of a predictive stroke and bleeding risk index in only 50% and 26% of patients, respectively. There were over- and underestimation of stroke and bleeding risk in a large proportion of patients. Antithrombotic therapy included warfarin (90%); 24% of patients had a time in the therapeutic range (TTR) < 50%, 9% between 50% and 60%, 11% between 60% and 70%, and 56% had a TTR ≥ 70%. CONCLUSIONS: In a large Canadian AF population, primary care physicians did not provide a stroke or bleeding risk in a substantial proportion of their AF patients. When estimates were provided, they were on the basis of a predictive stroke and bleeding risk index in less than half of the patients. Furthermore, there was under- and overestimation of stroke and bleeding risk in a substantial proportion of patients. As many as 1 in 3 patients receiving warfarin have their TTR < 60%. These findings suggest an opportunity to enhance knowledge translation to primary care physicians.


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Patient Education as Topic , Risk Assessment , Stroke/prevention & control , Aged , Aged, 80 and over , Canada/epidemiology , Female , Humans , Incidence , Male , Prognosis , Risk Factors , Stroke/epidemiology , Stroke/etiology , Survival Rate/trends
18.
J Cardiovasc Electrophysiol ; 26(12): 1340-5, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26471861

ABSTRACT

INTRODUCTION: Medtronic's Lead Integrity Alert (LIA) software algorithm is useful for detecting abnormal parameters across various ICD-lead families. However, its utility in the assessment of the Biotronik Linox™ family of high-voltage (HV) leads is unknown. METHODS: We conducted a retrospective cohort study to assess the performance of the LIA algorithm to detect abnormalities and lead failure in Linox ICD-leads. All LIA-enabled Medtronic devices connected to an active Linox lead were included. The alerts were adjudicated by 2 blinded electrophysiologists and correlated with clinical data. RESULTS: Between 2008 and 2012, data from 208 patients with 564 patient-years of follow-up were available for analysis. The median follow-up duration was 32 (IQR 21-41 months). Twenty-one LIA triggers were noted in 20 different patients. The median delay until a positive LIA was 32 months (IQR 21-41 months) postimplant with a 5-year lead survival free from LIA of 76%. Ninety-five percent (19/20) LIA alerts were true lead failures. The most common LIA triggers were short V-V intervals (85%) and nonsustained ventricular tachycardia (85%). Abrupt changes of the ICD-lead impedance occurred in 5/20 triggers. Inappropriate ICD-shocks were strongly associated with a positive LIA (30% vs. 7.4%; P = 0.006). Of the explanted Linox leads 53% had visible abnormalities. The sensitivity, specificity, and positive predictive value for lead failure in the presence of a LIA trigger were 87%, 99.5%, and 95.2%, respectively. CONCLUSIONS: A positive LIA trigger in Biotronik Linox ICD-leads is highly predictive of lead failure. LIA is useful in ongoing surveillance of lead performance.


Subject(s)
Algorithms , Defibrillators, Implantable , Tachycardia, Ventricular/therapy , Aged , Atrial Fibrillation/physiopathology , Atrial Fibrillation/therapy , Cohort Studies , Death, Sudden, Cardiac/prevention & control , Disease-Free Survival , Electrocardiography , Equipment Failure , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Tachycardia, Ventricular/physiopathology , Treatment Failure
19.
Circ Cardiovasc Qual Outcomes ; 8(2 Suppl 1): S21-30, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25714829

ABSTRACT

BACKGROUND: Social health is a dimension of quality of life, and refers to people's involvement in, and satisfaction with social roles, responsibilities, and activities. The implantable cardioverter-defibrillator is associated with changes in overall quality of life, but little is known about sex differences in individual trajectories of change in social health. METHODS AND RESULTS: We prospectively measured changes in 3 subscales of the SF-36v2 generic health questionnaire (role physical, role emotional, and social functioning), 2 Patient-Reported Outcomes Measurement Information System short forms (satisfaction with participation in social roles and satisfaction with participation in discretionary social activities), and the Florida Patient Acceptance Survey before and at 1, 2, and 6 months after implantation. Individual growth models of temporal change were estimated. The scores of the 6 indicators improved with time. The unconditional model demonstrated significant (fixed effects: P<0.05; covariance parameters: P<0.10) residual variability in the individual trajectories. In the conditional model, men and women differed significantly in their rates of change in the scores of 3 of the 6 measures. Although men's mean scores exceeded women's mean scores on all indicators at baseline (range of relative mean difference: 11.0% to 17.8%), the rate of women's change resulted in a reversal in relative standing at 6 months after implantation, with the mean scores of women exceeding the men's by 4.5% to 5.6%. CONCLUSIONS: Men and women differed in their trajectories of change in social health, both in terms of their starting points (ie, baseline scores) and their rates of change.


Subject(s)
Defibrillators, Implantable , Electric Countershock/instrumentation , Quality of Life , Social Behavior , Adult , Aged , Electric Countershock/adverse effects , Emotions , Female , Health Status Disparities , Humans , Interpersonal Relations , Longitudinal Studies , Male , Middle Aged , Patient Satisfaction , Prospective Studies , Sex Factors , Social Responsibility , Surveys and Questionnaires , Time Factors , Treatment Outcome
20.
Future Cardiol ; 10(3): 319-22, 2014 May.
Article in English | MEDLINE | ID: mdl-24976467

ABSTRACT

Barrett PM, Komatireddy R, Haaser S et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am. J. Med. 127(1), 95.e11­95.e17 (2014). The investigation of cardiac arrhythmias in the outpatient ambulatory setting has traditionally been initiated with the Holter monitor. Using the continuous recording over 24 or 48 h, the Holter monitor permits the detection of baseline rhythm, dysrhythmia and conduction abnormalities, including heart block and changes in the ST segment that may indicate myocardial ischemia. However, apart from the bulkiness and inconvenience of the device itself, the lack of extended monitoring results in a diagnostic yield of typically less than 20%. In this study by Barrett et al., 146 patients referred for the evaluation of cardiac arrhythmia were prospectively enrolled to wear both the 24-h Holter monitor and 14-day adhesive patch monitor (Zio Patch) simultaneously. The primary outcome was the detection of any one of six arrhythmias: supraventricular tachycardia, atrial fibrillation/flutter, pause >3 s, atrioventricular block, ventricular tachycardia, or polymorphic ventricular tachycardia/fibrillation. The adhesive patch monitor detected more arrhythmia events compared with the Holter monitor over the total wear time (96 vs. 61 events; p < 0.001), although the Holter monitor detected more events during the initial 24-h monitoring period (61 vs. 52 events; p = 0.013). Novel, single-lead, intermediate-duration, user-friendly adhesive patch monitoring devices, such as the Zio Patch, represent the changing face of ambulatory ECG monitoring. However, the loss of quality, automated rhythm analysis and inability to detect myocardial ischemia continue to remain important issues that will need to be addressed prior to the implementation of these new devices.


Subject(s)
Arrhythmias, Cardiac/diagnosis , Electrocardiography, Ambulatory , Electrocardiography/methods , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...